Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective
Journal of Cellular and Molecular Medicine · 2024-01 · 28 (2)
DOI: 10.1111/jcmm.17993 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 17.10.2023. Verfasst von Naif H Ali und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Medical College, Najran University, Najran, Saudi Arabia. Hauptthemen laut MEDLINE: Alzheimer Disease, Neurodegenerative Diseases. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Witten-Herdecke Germany.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is a heterogeneous neurodegenerative disease with multifaceted neuropathological disorders. AD is characterized by intracellular accumulation of phosphorylated tau proteins and extracellular deposition of amyloid beta (Aβ). Various protease enzymes, including neprilysin (NEP), are concerned with the degradation and clearance of Aβ. Indeed, a defective neuronal clearance pathway due to the dysfunction of degradation enzymes might be a possible mechanism for the accumulation of Aβ and subsequent progression of AD neuropathology. NEP is one of the most imperative metalloproteinase enzymes involved in the clearance of Aβ. This review aimed to highlight the possible role of NEP inhibitors in AD. The combination of sacubitril and valsartan which is called angiotensin receptor blocker and NEP inhibitor (ARNI) may produce beneficial and deleterious effects on AD neuropathology. NEP inhibitors might increase the risk of AD by the inhibition of Aβ clearance, and increase brain bradykinin (BK) and natriuretic peptides (NPs), which augment the pathogenesis of AD. These verdicts come from animal model studies, though they may not be applied to humans. However, clinical studies revealed promising safety findings regarding the use of ARNI. Moreover, NEP inhibition increases various neuroprotective peptides involved in inflammation, glucose homeostasis and nerve conduction. Also, NEP inhibitors may inhibit dipeptidyl peptidase 4 (DPP4) expression, ameliorating insulin and glucagon‐like peptide 1 (GLP‐1) levels. These findings proposed that NEP inhibitors may have a protective effect against AD development by increasing GLP‐1, neuropeptide Y (NPY) and substance P, and deleterious effects by increasing brain BK. Preclinical and clinical studies are recommended in this regard.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Medical College, Najran University, Najran, Saudi Arabia.
- Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
- Clinical Neurosciences Department, College of Medicine, King Faisal University, Hofuf, Saudi Arabia.
- Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, New South Wales, Australia.
- AFNP Med, Wien, Austria.
- Department of Surgery II, University Hospital Witten-Herdecke, University of Witten-Herdecke, Wuppertal, Germany.
ORCID-Profile: Athanasios Alexiou, Hebatallah M Saad
Förderung
- University of Witten-Herdecke Germany
Zitieren
APA
Ali, N. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alnaaim, S. A., Alexiou, A., Papadakis, M., Khalifa, A. A., Saad, H. M., & Batiha, G. E. (2024). Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective. Journal of Cellular and Molecular Medicine, 28(2). https://doi.org/10.1111/jcmm.17993
Vancouver
Ali NH, Al-Kuraishy HM, Al-Gareeb AI, Alnaaim SA, Alexiou A, Papadakis M, et al. Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective. Journal of Cellular and Molecular Medicine. 2024;28(2). doi:10.1111/jcmm.17993
BibTeX
@article{Ali2024,
author = {Ali, Naif H and Al-Kuraishy, Hayder M and Al-Gareeb, Ali I and Alnaaim, Saud A and Alexiou, Athanasios and Papadakis, Marios and Khalifa, Asmaa A and Saad, Hebatallah M and Batiha, Gaber El-Saber},
title = {Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
volume = {28},
number = {2},
doi = {10.1111/jcmm.17993}
}
EUVIMED